28 related articles for article (PubMed ID: 17717668)
1. A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer.
Ghosn M; Aftimos P; Farhat FS; Kattan JG; Hanna C; Haddad N; Nasr F; Chahine G
Med Oncol; 2011 Dec; 28 Suppl 1():S142-51. PubMed ID: 21136213
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer.
Gampenrieder SP; Bartsch R; Matzneller P; Pluschnig U; Dubsky P; Gnant MX; Zielinski CC; Steger GG
Breast Care (Basel); 2010; 5(3):158-162. PubMed ID: 21048830
[TBL] [Abstract][Full Text] [Related]
3. A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Orphanos G; Alexopoulos A; Malliou S; Ioannidis G; Ardavanis A; Kandylis C; Stavrakakis J; Rigatos G
J Cancer Res Clin Oncol; 2010 Jan; 136(1):115-21. PubMed ID: 19672628
[TBL] [Abstract][Full Text] [Related]
4. Weekly docetaxel in the treatment of metastatic breast cancer.
Palmeri L; Vaglica M; Palmeri S
Ther Clin Risk Manag; 2008 Oct; 4(5):1047-59. PubMed ID: 19209285
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Rivera F; Massutí B; Salcedo M; Sastre J; Martínez Galán J; Valladares-Ayerbes M; Serrano R; García de Paredes ML; Manzano JL; Galán M; Alsina M; Yuste Izquierdo AL; López C; Díaz-Rubio E; Conde V; Reboredo M; Cano MT; Pachón V; Aranda E
Cancer Chemother Pharmacol; 2015 Feb; 75(2):319-24. PubMed ID: 25491381
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
Mrozek E; Ramaswamy B; Young D; Rhoades CA; Kendra K; Allen J; Moore T; Hauger M; Watson H; Merriman N; Nadella P; Villalona-Calero M; Shapiro CL
Clin Breast Cancer; 2006 Jun; 7(2):141-5. PubMed ID: 16800973
[TBL] [Abstract][Full Text] [Related]
10. Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial.
Ghosn M; Kattan J; Farhat F; Younes F; Nasr F; Moukadem W; Gasmi J; Chahine G;
Cancer Chemother Pharmacol; 2008 Jun; 62(1):11-8. PubMed ID: 17717668
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine-docetaxel combination treatment.
Mandelblat J; Bashir T; Budman DR
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1169-78. PubMed ID: 17020452
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of capecitabine in breast cancer.
O'Shaughnessy JA
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S20-5. PubMed ID: 12756075
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
